Tenofovir disoproxil fumarate
Regulatory milestones approvals, filings & regulatory actions · 18 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (16) | US (FDA) | VIREAD | — | 2003-08-15 – 2018-12-11 | fda.gov ↗ |
| Approved | EU (EMA) | Viread | — | 2002-02-04 | europa.eu ↗ |
| Approved | US (FDA) | VIREAD | — | 2001-10-26 | fda.gov ↗ |
Trials 265 · started per year
Also used as a comparator or background therapy in 182 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07553767 Background | Mar 2026 → Dec 2034 expected | chronic hepatitis B virus infection, hepatocellular carcinoma | Ningbo No.2 Hospital | Not yet recruiting | No outcome recorded |
| Phase 115 trials | ||||||
| Phase 1 | NCT05763576 Background | Apr 2023 → Dec 2024 | chronic hepatitis B virus infection | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1 | NCT05423106 Background | Jul 2022 → Mar 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05123599 Background | Dec 2021 → Jul 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04760691 Comparator | Mar 2021 → Mar 2025 | HIV infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT03186482 Comparator | Jun 2017 → Jan 2018 | HIV infectious disease | St. Stephens Clinical Research | Completed | No outcome recorded |
| Phase 1 | NCT02908191 Background | Nov 2016 → Mar 2018 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT02904369 Comparator | Oct 2016 → Nov 2017 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT02722343 Comparator | Apr → Aug 2016 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT02556268 Background | Feb → Dec 2016 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT02589457 Comparator | Oct → Dec 2015 | chronic hepatitis B virus infection | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02006264 Comparator | Nov 2013 → Nov 2014 | HIV infectious disease | Albert Einstein College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01080820 Background | Jun → Dec 2010 | — | Jazz Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01040091 Comparator | Dec 2009 → Apr 2014 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00903084 Comparator | Jun 2009 → Jun 2010 | HIV infectious disease | Public Health Foundation Enterprises, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00076791 Comparator | Mar 2004 → Mar 2010 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT06150014 Comparator | Dec 2023 → Dec 2025 overdue | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03435146 Background | Jan 2018 → Dec 2022 | HIV infectious disease, respiratory tract infectious disorder | The Aurum Institute NPC | Completed | No outcome recorded |
| Phase 1/2 | NCT03109730 Background | Jun 2017 → Mar 2018 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1/2 | NCT02022657 Comparator | Apr 2014 → Nov 2016 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1/2 | NCT01632891 Background | Jan 2014 → Jun 2016 | HIV infectious disease, parasitemia | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 1/2 | NCT00036634 Comparator | Mar 2002 → Feb 2003 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 249 trials | ||||||
| Phase 2 | NCT05652478 Comparator | Jul 2026 → Jan 2028 expected | cardiomyopathy hypogonadism metabolic anomalies | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 2 | NCT07288190 Background | May 2026 → May 2028 expected | HIV infectious disease, pregnancy disorder | HIV Prevention Trials Network | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06566248 Comparator | Mar → Sep 2024 | chronic hepatitis B virus infection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06631365 Background | Oct 2023 → Jan 2025 overdue | HIV infectious disease | Public Health Foundation Enterprises, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05275023 Background | Jun 2022 → Dec 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05458765 Comparator | Jun 2022 → Dec 2023 | — | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 2 | NCT05238844 Background | Apr → May 2022 | chronic hepatitis B virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT05256823 Background | Feb 2022 → Nov 2023 | — | Lai Wei | Unknown | No outcome recorded |
| Phase 2 | NCT05005507 Background | Nov → Dec 2021 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04820686 Background | May 2021 → Mar 2023 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04847440 Comparator | Mar 2021 → Sep 2022 | chronic hepatitis B virus infection, hepatitis D virus infection | Antios Therapeutics, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT04585789 Background | Mar 2021 → Feb 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04667104 Background | Feb 2021 → May 2022 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04454567 Background | Nov 2020 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT04824131 Background | Nov 2020 → Jan 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04535544 Background | Sep 2020 → Oct 2023 | hepatitis D virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04439539 Background | Sep 2020 → Aug 2023 | chronic hepatitis B virus infection | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT04465916 Background | May 2020 → Jun 2021 | chronic hepatitis B virus infection | Enyo Pharma | Terminated | No outcome recorded |
| Phase 2 | NCT04692077 Background | Feb 2020 → Jul 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04133259 Background | Dec 2019 → Apr 2022 | chronic hepatitis B virus infection | Henlix, Inc | Unknown | No outcome recorded |
| Phase 2 | NCT04129554 Background | Nov 2019 → Jul 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT03982186 Background | Aug 2019 → Mar 2021 | chronic hepatitis B virus infection | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT04012931 Background | Jul 2019 → Feb 2023 | HIV infectious disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03780543 Comparator | Dec 2018 → Apr 2021 | chronic hepatitis B virus infection | Assembly Biosciences | Terminated | No outcome recorded |
| Phase 2 | NCT03576066 Background | Jun 2018 → Jul 2019 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 2 | NCT03491553 Background | Apr 2018 → Mar 2019 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT03272347 Comparator | Nov 2017 → Mar 2021 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT02862548 Comparator | Sep 2016 → Feb 2018 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02565719 Background | Mar 2016 → May 2019 | chronic hepatitis B virus infection | Replicor Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02579382 Background | Nov 2015 → Jan 2017 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT02415595 Background | May 2015 → May 2016 | HIV infectious disease | ViiV Healthcare | Terminated | No outcome recorded |
| Phase 2 | NCT02174276 Background | Jul 2014 → Feb 2016 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01687218 Comparator | Sep 2013 → May 2015 | HIV infectious disease | CONRAD | Completed | No outcome recorded |
| Phase 2 | NCT01943799 Background | Sep 2013 → Sep 2014 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01737359 Comparator | Dec 2012 → Feb 2013 | HIV infectious disease | RFS Pharma, LLC | Terminated | No outcome recorded |
| Phase 2 | NCT01632345 Background | Oct 2012 → Dec 2014 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01403051 Background | Sep 2011 → Feb 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01254656 Background | Feb 2011 → Apr 2013 | — | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00799864 Background | Jan 2011 → Aug 2022 | — | Janssen Sciences Ireland UC | Completed | No outcome recorded |
| Phase 2 | NCT00959894 Background | Sep 2009 → Feb 2014 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00892437 Background | May → Dec 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00824421 Background | Feb 2009 → Oct 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00752856 Comparator | Aug 2008 → May 2011 | HIV infectious disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 2 | NCT00551018 Comparator | Dec 2007 → May 2010 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00110305 Background | Jun 2005 → Dec 2011 | HIV infectious disease | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00119379 Comparator | Apr 2005 → Oct 2008 | HIV infectious disease, lipodystrophy, nutritional disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00131677 Comparator | Feb 2005 → Aug 2009 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00046033 Background | ? → Mar 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00027339 Background | ? → Jun 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02016924 Background | Jan 2014 → Jun 2025 overdue | AIDS | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT00448669 Comparator | Mar 2007 → Mar 2011 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/3 | NCT00391638 Background | Jan 2007 → May 2011 | HIV infectious disease, hepatitis B virus infection | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
| Phase 350 trials | ||||||
| Phase 3 | NCT06203132 Background | Jan 2025 → Nov 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT06630299 Comparator | Oct 2024 → Apr 2026 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05813964 Comparator | Jun 2024 → Oct 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 3 | NCT06273943 Comparator | Apr 2024 → Oct 2025 overdue | — | ANRS, Emerging Infectious Diseases | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06138600 Comparator | Nov 2023 → Oct 2025 | HIV infectious disease | University of Witwatersrand, South Africa | Unknown | No outcome recorded |
| Phase 3 | NCT05154747 Comparator | Jun 2023 → Mar 2025 | HIV infectious disease | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT04937881 Comparator | Jun 2022 → Apr 2023 | HIV infectious disease | University of California, Los Angeles | Completed | No outcome recorded |
| Phase 3 | NCT04644029 Comparator | Feb 2021 → Jul 2023 | HIV infectious disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 3 | NCT04543565 Comparator | Sep 2020 → Oct 2022 | chronic hepatitis B virus infection | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04846491 Comparator | Dec 2019 → Nov 2023 | chronic hepatitis B virus infection | Xiamen Amoytop Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03595709 Background | Dec 2018 → Mar 2019 | HIV infectious disease | Yu-Jay Corp. | Completed | No outcome recorded |
| Phase 3 | NCT03563742 Background | Sep 2018 → Jun 2021 | HIV infectious disease | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT03631732 Comparator | Aug 2018 → Aug 2019 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02967939 Comparator | Mar 2017 → Jan 2019 | chronic hepatitis B virus infection | Dong-A ST Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03122262 Comparator | Jan 2017 → Apr 2022 | HIV infectious disease | Professor Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT02831673 Comparator | Jul 2016 → Mar 2018 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02831764 Comparator | Jul 2016 → Apr 2018 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
| Phase 3 | NCT02777229 Background | Jul 2016 → Jul 2018 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02805738 Comparator | Apr 2016 → Nov 2017 | chronic hepatitis B virus infection | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 3 | NCT02603107 Background | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02273765 Background | Sep 2015 → Nov 2018 | HIV infectious disease, tuberculosis | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT02792088 Comparator | Jul 2015 → Feb 2020 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Completed | No outcome recorded |
| Phase 3 | NCT02836249 Comparator | Jun 2015 → Mar 2017 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02836236 Comparator | Jun 2015 → Apr 2017 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02186574 Comparator | May 2015 → Feb 2021 | hepatitis B virus infection, non-Hodgkin lymphoma | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT02269917 Comparator | Mar 2015 → Feb 2017 | HIV infectious disease | Janssen R&D Ireland | Completed | No outcome recorded |
| Phase 3 | NCT02345226 Comparator | Jan 2015 → Jun 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02345252 Comparator | Jan 2015 → Jun 2016 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02275780 Background | Dec 2014 → Sep 2016 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02302547 Background | Dec 2014 → Aug 2017 | HIV infectious disease | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02131233 Background | May 2014 → Dec 2015 | HIV infectious disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01709084 Background | Oct 2013 → Oct 2015 | HIV infectious disease | Janssen-Cilag International NV | Completed | No outcome recorded |
| Phase 3 | NCT01435018 Background | Oct 2013 → Mar 2018 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT01940341 Comparator | Sep 2013 → Sep 2015 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01940471 Comparator | Sep 2013 → Nov 2015 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02670772 Comparator | Jul 2012 → Dec 2014 | AIDS | Willem Daniel Francois Venter | Completed | No outcome recorded |
| Phase 3 | NCT01473472 Comparator | Jan 2012 → Jun 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 3 | NCT01475838 Comparator | Nov 2011 → Nov 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01363011 Background | May 2011 → Jan 2013 | AIDS | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01309243 Background | Feb 2011 → Sep 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01252940 Background | Nov 2010 → Jan 2012 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01108510 Background | Apr 2010 → Nov 2011 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00811954 Background | May 2009 → Jun 2013 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT00708162 Background | Jul 2008 → Dec 2010 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00557245 Comparator | May 2008 → Oct 2013 | HIV infectious disease | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT00089505 Background | Nov 2006 → Aug 2010 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 3 | NCT00262522 Comparator | Nov 2005 → Jul 2008 | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 3 | NCT00272779 Comparator | Nov 2005 → Jun 2007 | HIV infectious disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00105079 Background | Apr 2005 → Aug 2007 | HIV infectious disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00043966 Background | Jul 2002 → ? | HIV infectious disease | Abbott | Completed | No outcome recorded |
| Phase 436 trials | ||||||
| Phase 4 | NCT07673965 Background | Aug 2026 → Aug 2027 expected | HIV infectious disease | University of Witwatersrand, South Africa | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07631897 Background | Jun 2026 → Jun 2028 expected | HIV infectious disease, tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07258251 Background | Jan 2026 → Dec 2028 expected | chronic hepatitis B virus infection | The Task Force for Global Health | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07573943 Background | May 2024 → Dec 2026 expected | chronic hepatitis B virus infection | The Second Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 4 | NCT06158126 Comparator | Apr 2024 → Dec 2026 expected | pregnancy disorder | University of North Carolina, Chapel Hill | Recruiting | No outcome recorded |
| Phase 4 | NCT05630638 Comparator | Oct 2023 → Jul 2028 expected | HIV infectious disease | University of Liverpool | Recruiting | No outcome recorded |
| Phase 4 | NCT05122754 Comparator | Dec 2021 → Feb 2024 | HIV infectious disease | Shanghai Public Health Clinical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04880395 Comparator | May 2021 → May 2024 | HIV infectious disease | Fundación Huésped | Completed | No outcome recorded |
| Phase 4 | NCT04331704 Background | Jan 2021 → Dec 2025 overdue | alcohol-related disorders | University of Florida | Recruiting | No outcome recorded |
| Phase 4 | NCT04640129 Comparator | Jan 2021 → Nov 2025 | fibrotic liver disease | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 4 | NCT04549467 Comparator | Nov 2020 → Sep 2023 | HIV infectious disease | Fundacion IDEAA | Completed | No outcome recorded |
| Phase 4 | NCT04202536 Comparator | May 2019 → Jun 2021 | chronic hepatitis B virus infection | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT03348163 Comparator | Jun 2018 → Dec 2020 | HIV infectious disease | The University of Texas Health Science Center, Houston | Terminated | No outcome recorded |
| Phase 4 | NCT03387462 Background | Feb → Aug 2018 | — | Public Health Foundation Enterprises, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03357822 Background | Jan 2018 → Jan 2022 | chronic hepatitis B virus infection | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03126370 Background | Jan 2018 → Jul 2019 | coinfection, hepatitis C virus infection | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT03356834 Comparator | Dec 2017 → Oct 2024 | chronic hepatitis B virus infection | Humanity and Health Research Centre | Completed | No outcome recorded |
| Phase 4 | NCT03241641 Comparator | Oct 2017 → Mar 2021 | chronic hepatitis B virus infection | Young-Suk Lim | Completed | No outcome recorded |
| Phase 4 | NCT02815566 Comparator | Sep 2017 → Feb 2021 | HIV infectious disease, osteoporosis | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 4 | NCT03013556 Comparator | Nov 2016 → Dec 2021 | chronic hepatitis B virus infection | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02322099 Comparator | May 2016 → Sep 2019 | disease of bone structure | University College Dublin | Terminated | No outcome recorded |
| Phase 4 | NCT02774837 Background | Apr 2016 → Jul 2020 | chronic hepatitis B virus infection | Seng Gee Lim | Unknown | No outcome recorded |
| Phase 4 | NCT02560649 Comparator | May 2015 → Aug 2016 | chronic hepatitis B virus infection | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02401230 Comparator | Mar 2015 → Jan 2017 | HIV infectious disease | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02159599 Comparator | Jul 2014 → Apr 2016 | HIV infectious disease | Fundacion SEIMC-GESIDA | Completed | No outcome recorded |
| Phase 4 | NCT01147107 Background | Feb 2014 → Jun 2016 | HIV infectious disease, chronic hepatitis C virus infection | University of Hawaii | Completed | No outcome recorded |
| Phase 4 | NCT01869634 Comparator | Jun 2013 → Dec 2016 | HIV infectious disease | University of California, Davis | Completed | No outcome recorded |
| Phase 4 | NCT01320943 Comparator | Apr 2011 → Jul 2016 | chronic hepatitis B virus infection | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01379508 Comparator | Mar 2011 → Dec 2015 | chronic hepatitis B virus infection | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01340950 Comparator | Jul 2010 → Jul 2014 | HIV infectious disease, central nervous system disorder, dementia | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT00647244 Comparator | Jun 2008 → Aug 2010 | HIV infectious disease | Aarhus University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00627055 Comparator | May 2008 → Nov 2010 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
| Phase 4 | NCT00552240 Comparator | Sep 2007 → Mar 2010 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 4 | NCT00648817 Comparator | Jul 2006 → Nov 2007 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00979706 Comparator | Mar 2005 → Nov 2014 | HIV infectious disease | Juan A. Arnaiz | Completed | No outcome recorded |
| Phase 4 | NCT00643968 Comparator | Mar 2003 → Jun 2005 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase not applicable21 trials | ||||||
| — | NCT07497594 Comparator | Feb 2026 → Feb 2029 expected | — | Oswaldo Cruz Foundation | Recruiting | No outcome recorded |
| — | NCT06947356 Comparator | May 2025 → May 2028 expected | hepatitis B virus infection | Guangzhou 8th People's Hospital | Recruiting | No outcome recorded |
| — | NCT06323681 Comparator | Feb 2024 → Feb 2027 expected | chronic hepatitis B virus infection | Qing XIe | Recruiting | No outcome recorded |
| — | NCT05793268 Comparator | Dec 2022 → Dec 2025 overdue | chronic hepatitis B virus infection | E-DA Hospital | Active not recruiting | No outcome recorded |
| — | NCT04501224 Comparator | Aug 2020 → Oct 2021 | chronic hepatitis B virus infection, cirrhosis of liver | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03957629 Comparator | Nov 2019 → Jul 2021 | fibrotic liver disease, hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03920618 Comparator | Feb 2019 → Dec 2024 overdue | hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT03920605 Comparator | Feb 2019 → Oct 2021 | fibrotic liver disease, hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT03919565 Comparator | Feb 2019 → Oct 2021 | chronic hepatitis B virus infection, fibrotic liver disease | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT04196998 Comparator | Jan 2019 → Dec 2023 | cirrhosis of liver, hepatitis B virus infection | Third Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02827643 Comparator | Jun 2016 → Mar 2017 | bone disorder | Mahidol University | Unknown | No outcome recorded |
| — | NCT02510963 Comparator | Nov 2015 → Jun 2017 | chronic hepatitis B virus infection | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT01918631 Comparator | Aug 2013 → Jan 2017 | chronic hepatitis B virus infection | Chinese University of Hong Kong | Completed | No outcome recorded |
| — | NCT01293123 Background | Dec 2011 → Jun 2013 | HIV infectious disease | University of California, San Diego | Terminated | No outcome recorded |
| — | NCT01450189 Comparator | Oct 2011 → Jul 2014 | HIV infectious disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| — | NCT00973219 Comparator | Sep 2009 → Oct 2019 | chronic hepatitis B virus infection | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT00863668 Background | Mar 2009 → Mar 2010 | HIV infectious disease | University of Minnesota | Withdrawn | No outcome recorded |
| — | NCT00608569 Background | Mar 2009 → Sep 2012 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| — | NCT00734344 Comparator | Sep 2008 → Aug 2012 | — | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00051831 Background | Oct 2003 → Dec 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00028366 Background | ? → Jul 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05683548 Background | — | chronic hepatitis B virus infection, cirrhosis of liver, esophageal varices, hepatitis D virus infection +1 | Replicor Inc. | No longer available | No outcome recorded |
Press releases naming this drug 155 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-28 | Gilead Sciences | FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six gilead.com ↗ |
| 2022-11-02 | Gilead Sciences | U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients gilead.com ↗ |
| 2019-08-09 | Gilead Sciences | China National Medical Products Administration Approves Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-03-26 | Gilead Sciences | Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women gilead.com ↗ |
| 2019-03-06 | Gilead Sciences | Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance gilead.com ↗ |
| 2018-12-04 | Gilead Sciences | China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-11-18 | Gilead Sciences | China National Medical Products Administration (NMPA) Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for Chronic Hepatitis B Virus (HBV) Infection gilead.com ↗ |
| 2018-10-30 | Gilead Sciences | Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ |
| 2018-10-03 | Gilead Sciences | Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy gilead.com ↗ |
| 2018-08-06 | Gilead Sciences | China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection gilead.com ↗ |
| 2018-07-24 | Gilead Sciences | Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States gilead.com ↗ |
| Show all 155 releases opens the full record — a long page | ||
Evidence & citations 21 cited values
Every value below carries the sentence it was read from. 477 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tenofovir disoproxil fumarate | “This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of...” NCT01632995 ↗367“The main objective of this study is to compare the mother-to-infant transmission rates of hepatitis B between pregnant women receiving treatment with tenofovir alafenamide and...” NCT06947356 ↗ “Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in...” PMID 26453773 ↗ Oct 2015 “A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among...” NCT02042001 ↗ “The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in...” NCT02836236 ↗ “This study aims: (1) to determine the optimal dose of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for daily oral pre-exposure prophylaxis (PrEP) during pregnancy...” NCT06435026 ↗ “Tenofovir Disoproxil Fumarate (nucleotide reverse transcriptase inhibitor) + Emtricitabine (nucleoside reverse transcriptase inhibitor) + third agent (boosted protease...” NCT02302547 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted...” NCT03126370 ↗ “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that is converted intracellularly to the active form, resulting in higher concentrations of TFV diphosphate in...” NCT05735535 ↗ “The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to...” NCT01651403 ↗ “The CASTLE Study was a 96 week randomized study comparing 300 mg of atazanavir once daily with 400 mg of lopinavir twice daily, each with low-dose ritonavir (100 mg) plus...” PMID 22121190 ↗ Nov 2011 “The purpose of this study is to quantify the magnitude and extent of infant exposure to daily emtricitabine (FTC) /tenofovir disoproxil fumarate (TDF) via maternal breastmilk...” NCT02776748 ↗ “Participants were prescribed coformulated (once-daily, oral tablet) tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg) as HIV PrEP and were followed up with HIV...” PMID 34217426 ↗ Jul 2021 “Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients...” NCT00335192 ↗ “We randomly assigned (1:1) participants to receive dolutegravir 50 mg plus lamivudine 300 mg or a three-drug regimen including dolutegravir 50 mg plus tenofovir disoproxil...” PMID 39826566 ↗ Jan 2025 “Levels of the active ingredients, Tenofovir disoproxil fumarate, emtricitabine, rilpivirine hydrochloride will be measured in in blood after the drug intake has been stopped in...” NCT01796431 ↗ “Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the...” NCT00110305 ↗ “The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate p.o. q.d. or EPZICOM™/KIVEXA™, a tablet containing...” NCT02275780 ↗ “The aim of this study was to investigate the effect on fasting lipid parameters of switching to tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) from abacavir (ABC)...” PMID 22910324 ↗ Aug 2012 “The primary objective of this study is to assess the efficacy of switching to tenofovir disoproxil fumarate (TDF) compared to continuing stavudine or zidovudine in maintaining...” NCT00528957 ↗ “tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic...” NCT02836249 ↗ “Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein...” PMID 20053692 ↗ Jan 2010 “Our goal was to study the impact of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on bone mineral density (BMD) in peri- and early...” PMID 36511389 ↗ Jan 2023 “Tenofovir amibufenamide (TMF) is a novel phosphoramidated prodrug of tenofovir with noninferior efficacy and better bone and renal safety to tenofovir disoproxil fumarate (TDF)...” PMID 36969889 ↗ Nov 2022 “The aim of this study was to investigate the impact of a tenofovir disoproxil fumarate (TDF) plus ritonavir-boosted protease inhibitor (PI/r) regimen on renal function in...” PMID 23815472 ↗ Jul 2013 “As of today, there is preclinical evidence, principally in vitro, indicating antiviral effect of Tenofovir Disoproxil Fumarate / Emtiricitabine (TDF/FTC) on the SARS-CoV-2 RNA...” NCT04519125 ↗ “The HIV-1 uninfected partner was randomized in a 1:1:1 ratio to one of three arms: once daily Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate...” NCT00557245 ↗ “Participants could choose between event-driven (2+1+1 dosing) and daily oral PrEP (tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg), switch regimen, and...” PMID 34048794 ↗ May 2021 “Participants will continue on their SOC NrtI, Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF) or Tenofovir Alafenamide (TAF) tablet QD (once daily) orally as per approved...” NCT03780543 ↗ “Participants were randomly assigned (1:1) to receive daily combined tenofovir disoproxil fumarate (245 mg) and emtricitabine (200 mg) either immediately or after a deferral...” PMID 26364263 ↗ Sep 2015 “Tenofovir disoproxil fumarate (tenofovir) has been associated with renal dysfunction in people infected with human immunodeficiency virus (HIV) receiving combination...” PMID 24829212 ↗ May 2014 “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗ “Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing...” NCT02322099 ↗ “Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) 100 mg doravirine, 300 mg lamivudine,300 mg tenofovir disoproxil fumarate equivalent to 245 mg de tenofovir...” NCT04233372 ↗ “BACKGROUND: Few data are available regarding the use of tenofovir disoproxil fumarate (TDF) during pregnancy for the prevention of mother-to-child transmission of hepatitis B...” PMID 27305192 ↗ Jun 2016 “Tenofovir disoproxil fumarate (TDF) has been approved worldwide for the treatment of adults with chronic hepatitis B and, in combination with other antiretroviral agents, HIV-1...” PMID 24148552 ↗ Oct 2013 “Two drugs are combined in an FDA-approved pill called TRUVADA, containing the HIV medications, tenofovir disoproxil fumarate 300mg and emtricitabine 200mg, taken as one pill once a day.” NCT00594646 ↗ “the co-formulated pre-exposure prophylaxis oral pill containing tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir, and FTC concurrently with the contraceptive injection DMPA” NCT03197961 ↗ “Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase.” PMID 19052126 ↗ Dec 2008 “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States.” NCT04666792 ↗ “Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection” NCT01844297 ↗ “Tenofovir alafenamide (TAF) has shown equivalent efficacy and improved safety profiles for patients with chronic hepatitis B (CHB) compared to tenofovir disoproxil fumarate (TDF).” PMID 30038044 ↗ Sep 2018 “will receive oral tenofovir disoproxil fumarate 300 milligrams combined with emtricitabine 200 milligrams in a fixed dose combination administered once daily on a continuous basis” NCT07497594 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily” NCT01286740 ↗ “A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) is the first complete HAART that is offered as one tablet once a day.” NCT00615745 ↗ “Tenofovir disoproxil fumarate (TDF) is a prodrug of TFV (tenofovir), an adenosine nucleoside monophosphonate (nucleotide) derivative with potent antiretroviral (ARV) activity.” NCT02006264 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.” NCT05763576 ↗ “This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks” NCT04429152 ↗ “coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men who have sex with men (MSM).” PMID 26123937 ↗ Jun 2015 “The availability of tenofovir disoproxil fumarate (DF) 300 mg offers new options in the creation of once-daily regimens with reduced potential for drug-drug-interactions.” NCT00324688 ↗ “currently either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg” NCT02591420 ↗ “Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz” NCT02827643 ↗ “The study drug will be administered at the standard dose used for the treatment and prevention of HIV (300mg tenofovir disoproxil fumarate, 200mg emtricitabine).” NCT05957913 ↗ “Administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)” NCT01943799 ↗ “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya” NCT03052010 ↗ “Medication: Tenofovir Disoproxil Fumarate (TDF); Administration Route: Oral Dosage: 300 mg/day or 300 mg every 2 days (if creatinine clearance is 30-50 ml/min)” NCT07054359 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal” NCT01309243 ↗ “Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks” NCT05182463 ↗ “tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r) at nine sites in Thailand.” PMID 23075703 ↗ Jul 2012 “Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food” NCT01495702 ↗ “Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.” PMID 35815468 ↗ Aug 2022 “Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks” NCT05256823 ↗ “Participants will take 300mg tenofovir disoproxil fumarate/200 mg emtricitabine, once per day, and one placebo capsule per day, oral capsule for 90 days.” NCT06511063 ↗ “A Rollover Protocol to Provide Open-Label Emtricitabine/Tenofovir Disoproxil Fumarate Combination Product to Subjects Completing the GS-US-203-0107 Study” NCT00936715 ↗ “A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), A Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children With HIV Infection” NCT00024986 ↗ “FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.” NCT01403051 ↗ “Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF) combination is approved for HIV pre-exposure prophylaxis (PrEP) in men and women.” PMID 34041459 ↗ May 2021 “to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)” NCT03012607 ↗ “Maternal tenofovir disoproxil fumarate (TDF) therapy during late pregnancy can reduce mother-to-infant transmission of hepatitis B virus (HBV).” PMID 35789261 ↗ Feb 2023 “co-formulated Tenofovir Disoproxil Fumarate and Emtricitabine (FTC/TDF) plus combined ethinyl estradiol/levonorgestrel oral contraceptive (COC)” NCT07288190 ↗ “Delstrigo (300 mg of tenofovir disoproxil fumarate equivalent to 245 mg of tenofovir disoproxil, 300 mg of lamivudine and 100 mg of doravirine” NCT05289986 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.” NCT00507689 ↗ “A daily tablet containing 245 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada; Gilead Sciences) for up to 30 days.” NCT04331704 ↗ “fixed tenofovir disoproxil fumarate (300 mg once daily) plus either lamivudine (300 mg once daily) or emtricitabine (200 mg once daily).” PMID 38788744 ↗ May 2024 “Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert” NCT04454567 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT01108510 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT00892437 ↗ “Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection.” NCT00078182 ↗ “Truvada® (a fixed-dose combination tablet of emtricitabine \[FTC, 200 mg\] and tenofovir disoproxil fumarate \[TDF, 300 mg\])” NCT00324649 ↗ “96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily” NCT01340950 ↗ “once-daily tenofovir disoproxil fumarate/emtricitabine in individuals on successful efavirenz-based antiretroviral therapy” PMID 19561519 ↗ Aug 2009 “PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study.” NCT02043015 ↗ “Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum” NCT03343431 ↗ “Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase” PMID 20955704 ↗ Oct 2010 “All participants will be offered daily oral emtricitabine/tenofovir disoproxil fumarate for Pre-exposure Prophylaxis.” NCT02584140 ↗ “Once-daily dolutegravir 50 mg with tenofovir disoproxil fumarate 300 mg and lamivudine 300 mg was initiated on day 0” PMID 40349709 ↗ May 2025 “Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination” NCT05154747 ↗ “Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg” NCT02397096 ↗ “Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)” NCT02131233 ↗ “tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food” NCT01533259 ↗ “single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovir disoproxil fumarate (300 mg)” PMID 28259776 ↗ Mar 2017 “Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators” NCT01334567 ↗ “Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.” NCT02401230 ↗ “This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).” NCT00036634 ↗ “600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily” NCT02556268 ↗ “Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.” NCT02985996 ↗ “Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.” NCT03348163 ↗ “placebo with nucleos(t)ide analogue (NA) (tenofovir disoproxil fumarate/entecavir) or JNJ-56136379 alone” PMID 36697207 ↗ Jan 2023 “Tenofovir disoproxil fumarate was administered once daily, one tablet at a time, with or without food.” NCT05122754 ↗ “100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)” NCT04665375 ↗ “daily oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for the prevention of HIV infection” PMID 34379922 ↗ Aug 2021 “TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg)” NCT02150993 ↗ “each in combination with tenofovir disoproxil fumarate and emtricitabine (TDF/FTC) (300/200 mg QD)” PMID 30352054 ↗ Oct 2018 “The tablets contain 200mg emtricitabine combined with 300mg tenofovir disoproxil fumarate (300mg).” NCT02722343 ↗ “Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo)” NCT03595709 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)” NCT02273765 ↗ “using Tenofovir Disoproxil Fumarate plus Emtricitabine (FTC/TDF) in men and women at risk for HIV” NCT00971230 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)” NCT06158126 ↗ “tenofovir disoproxil fumarate (TDF) in an open-label, longterm extension of two phase 3 studies” PMID 23939953 ↗ Feb 2014 “Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen” NCT01855867 ↗ “stribild (STB; elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF))” NCT02246998 ↗ “containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead)” NCT02593409 ↗ “Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily” NCT00737568 ↗ “Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)” NCT04140266 ↗ “either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]” NCT03982186 ↗ “switch these antiretrovirals to tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)” NCT00389194 ↗ “ETR 400 mg plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) 300/200 mg once daily” PMID 26263403 ↗ Aug 2015 “DTG plus Tenofovir disoproxil fumarate (TDF)/XTC: Emtricitabine or lamivudine (FTC or 3TC).” PMID 40874763 ↗ Feb 2026 “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults” PMID 28873128 ↗ Nov 2017 “Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens” NCT02862548 ↗ “coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate” PMID 24908550 ↗ Jun 2014 “Antiretroviral Agents, TMC278 and Tenofovir Disoproxil Fumarate (TDF), at Steady State” NCT01205139 ↗ “HUG116 tablet(Tenofovir Disoproxil) with Viread® tablet(Tenofovir Disoproxil Fumarate)” NCT02902523 ↗ “oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis” PMID 33222803 ↗ Oct 2020 “Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate” NCT01690403 ↗ “Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors;” NCT06566248 ↗ “Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents” PMID 22643350 ↗ May 2012 “Doravirine/Tenofovir Disoproxil Fumarate/Emtricitabine 100/300/300 mg (DOR/TDF/3TC)” NCT06602622 ↗ “Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily” NCT00507507 ↗ “Tenofovir disoproxil fumarate (TDF) is associated with a protective lipid profile” NCT05477407 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily” NCT01320943 ↗ “open-label tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC)” PMID 31355775 ↗ 2019 “each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).” NCT00552240 ↗ “tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B” NCT04846491 ↗ “200 mg of emtricitabine [FTC], 300 mg of tenofovir disoproxil fumarate [TDF]” NCT04778514 ↗ “200mg emtricitabine and 300mg of tenofovir disoproxil fumarate (as Truvada®)” NCT02022657 ↗ “Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate” NCT01480284 ↗ “tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine” PMID 29020293 ↗ Nov 2017 “placebo to match (PTM) emtricitabine/tenofovir disoproxil fumarate (F/TDF)” NCT04994509 ↗ “tenofovir disoproxil fumarate (F/TDF) as PrEP among transgender women and” PMID 38312459 ↗ Jan 2024 “Efavirenz (EFV) + Tenofovir Disoproxil Fumarate + Emtricitabine (TDF/FTC)” NCT00752856 ↗ “TDF = tenofovir disoproxil fumarate; FTC = emtrcitabine; MVC = maraviroc” NCT02431273 ↗ “Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily” NCT04925752 ↗ “Tenofovir disoproxil fumarate (TDF) may be used if TAF is unavailable.” NCT07258251 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily” NCT02579382 ↗ “emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen” PMID 24908551 ↗ Jun 2014 “oral PrEP with emtricitabine plus tenofovir disoproxil fumarate” PMID 28986029 ↗ Oct 2017 “tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg” PMID 41173578 ↗ Nov 2025 “tenofovir disoproxil fumarate plus lamivudine or emtricitabine” NCT04183738 ↗ “maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®” NCT00708162 ↗ “tenofovir disoproxil fumarate (300mg/tab, once per day)” NCT05793268 ↗ “Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).” NCT02269917 ↗ “Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread®)” NCT02479880 ↗ “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)” NCT04760691 ↗ “tenofovir disoproxil fumarate (TDF) (TDF-based group)” PMID 31339677 ↗ Jul 2019 “stavudine (d4T), tenofovir disoproxil fumarate (TDF)” NCT00039741 ↗ “Emtricitabine/Tenofovir Disoproxil Fumarate; Truvada” NCT03593655 ↗ “DTG/tenofovir disoproxil fumarate (TDF; Viread®)/3TC” NCT06630299 ↗ “including tenofovir disoproxil fumarate (TDF) 245mg” NCT06338826 ↗ “tenofovir disoproxil fumarate (TDF) (300 mg daily)” PMID 41644158 ↗ Feb 2026 “tenofovir disoproxil fumarate 300 mg PO once daily” NCT01293123 ↗ “tenofovir disoproxil fumarate (tenofovir DF; TDF)” NCT00352053 ↗ “emtricitabine and tenofovir disoproxil fumarate” NCT02148094 ↗ “Emtricitabine and tenofovir disoproxil fumarate” NCT00856323 ↗ “tenofovir disoproxil fumarate (TDF) 300 mg QD” NCT00262522 ↗ “Tenofovir disoproxil fumarate (TDF; Viread®)” NCT03491553 ↗ “Tenofovir Disoproxil Fumarate/Emtricitabine” NCT03834909 ↗ “Tenofovir disoproxil fumarate/emtricitabine” NCT03164564 ↗ “tenofovir disoproxil fumarate (TDF) 300 mg” NCT05813964 ↗ “tenofovir disoproxil fumarate (TDF) 300mg” NCT01602822 ↗ “Tenofovir Disoproxil Fumarate 300 mg q.d.” NCT02792088 ↗ “tenofovir disoproxil fumarate (TDF)/FTC” NCT04636437 ↗ “tenofovir disoproxil fumarate \[TDF\]” NCT04012931 ↗ “tenofovir disoproxil fumarate 300 mg” NCT00106379 ↗ “Drug: Tenofovir disoproxil fumarate” NCT00647244 ↗ “tenofovir disoproxil fumarate (TDF)” NCT02016924 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT03576066 ↗ “tenofovir disoproxil fumarate (TDF)” NCT02345252 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT04820686 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT02231281 ↗ “tenofovir disoproxil fumarate (TDF)” NCT00336778 ↗ “Tenofovir Disoproxil Fumarate 1T PO” NCT02589457 ↗ “tenofovir disoproxil fumarate (TDF)” NCT06337032 ↗ “tenofovir disoproxil fumarate (TDF)” NCT03631732 ↗ “Tenofovir Disoproxil Fumarate” NCT02231281 ↗ “Tenofovir disoproxil fumarate” NCT07573943 ↗ “Tenofovir disoproxil fumarate” NCT07553767 ↗ “Tenofovir disoproxil fumarate” NCT06631365 ↗ “Tenofovir disoproxil fumarate” NCT04133259 ↗ “Tenofovir Disoproxil Fumarate” NCT02670772 ↗ |
| Known as | BR-TND Tablet | “A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir...” NCT02920931 ↗ |
| Known as | GSK548470 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01475851 ↗ |
| Known as | HUG116 | “HUG116 tablet(Tenofovir Disoproxil) with Viread® tablet(Tenofovir Disoproxil Fumarate)” NCT02902523 ↗ |
| Known as | PMPA prodrug | “In this double-blind, placebo-controlled study, a total of 60 patients are randomized to receive PMPA prodrug at 1 of 5 doses or matching placebo tablets.” NCT00002396 ↗1“formerly known as PMPA prodrug” NCT00024986 ↗ |
| Known as | Qingzhong | “Qingzhong, a brand name of TDF, commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd., and Viread, another brand name of TDF, commercialized by GlaxoSmithKline,...” PMID 34222435 ↗ Jun 2021 |
| Known as | TDF | “This study will assess the uptake, acceptability, safety, and feasibility of HIV pre-exposure prophylaxis (PrEP), consisting of a once-daily fixed-dose combination tablet of...” NCT01632995 ↗189“Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in...” PMID 26453773 ↗ Oct 2015 “A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue TDF/FTC/Efavirenz (EFV) Treatment Among...” NCT02042001 ↗ “The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in...” NCT02836236 ↗ “BACKGROUND: New regimens may provide better tolerability, convenience, and safety for nonoccupational human immunodeficiency virus (HIV) postexposure prophylaxis (PEP). For...” PMID 37539061 ↗ Jul 2023 “This study aims: (1) to determine the optimal dose of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) for daily oral pre-exposure prophylaxis (PrEP) during pregnancy...” NCT06435026 ↗ “Both HIV and HBV can be treated with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC), so we evaluated the safety and efficacy of combination antiretroviral therapy...” PMID 26831232 ↗ Feb 2016 “In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) +...” PMID 38877762 ↗ Nov 2024 “Objective:To evaluate the effectiveness, safety, and tolerability of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) compared with...” NCT07075146 ↗ “Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC,...” NCT01363011 ↗ “Tenofovir alafenamide (TAF) is a novel prodrug of tenofovir (TFV) that is converted intracellularly to the active form, resulting in higher concentrations of TFV diphosphate in...” NCT05735535 ↗ “The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to...” NCT01651403 ↗ “The purpose of this study is to quantify the magnitude and extent of infant exposure to daily emtricitabine (FTC) /tenofovir disoproxil fumarate (TDF) via maternal breastmilk...” NCT02776748 ↗ “BACKGROUND: Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC)...” PMID 18042503 ↗ Nov 2007 “Investigational Product Tenofovir disoproxil fumarate / lamivudine / dolutegravir Dosage Formulation 300 mg / 300 mg / 50 mg fixed dose combination tablet Route of...” NCT06485154 ↗ “Determination of Plasma and Intracellular Levels of Nucleoside Reverse Transcriptase Inhibitors (NRTI) and of Nucleotide Analog Tenofovir Disoproxil Fumarate (TDF) in Patients...” NCT00335192 ↗ “The purpose of this study is to evaluate the antiviral activity and safety of tenofovir disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living...” NCT00736190 ↗ “The aim of this study was to investigate the effect on fasting lipid parameters of switching to tenofovir disoproxil fumarate (TDF) plus emtricitabine (FTC) from abacavir (ABC)...” PMID 22910324 ↗ Aug 2012 “In this study, we evaluated emtricitabine (F, FTC)/tenofovir (TFV) disoporoxil fumarate (TDF) pharmacokinetics (PK) among adolescent and young adult transgender persons...” PMID 35943868 ↗ Sep 2022 “tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic...” NCT02836249 ↗ “Participants will receive lopinavir/ritonavir twice daily for up to 104 weeks. Upon confirmation of virologic failure, emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)...” NCT00357552 ↗ “Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to...” NCT02831673 ↗ “This study aims to evaluate the safety and effectiveness of the tenofovir disoproxil fumarate (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen in antiretroviral therapy...” NCT01844297 ↗ “This study was designed to compare the efficacy between peg-IFN alpha combined with tenofovir (TDF) and TDF monotherapy for the clearance of HBsAg in NA-experienced patients...” PMID 34697111 ↗ Oct 2021 “Our goal was to study the impact of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) on bone mineral density (BMD) in peri- and early...” PMID 36511389 ↗ Jan 2023 “As of today, there is preclinical evidence, principally in vitro, indicating antiviral effect of Tenofovir Disoproxil Fumarate / Emtiricitabine (TDF/FTC) on the SARS-CoV-2 RNA...” NCT04519125 ↗ “Mothers with high-risk HBV (defined as viral load \<10\^6 and/or HBeAg positivity) will be treated with tenofovir disoproxil fumarate (TDF) to further reduce the risk of...” NCT03567382 ↗ “The study aimed to evaluate the efficacy and safety of tenofovir disoproxil fumarate (TDF) and entecavir hydrate (ETV) in nucleos(t)ide analog (NA)-naïve Japanese chronic...” PMID 28374496 ↗ May 2017 “Participants will receive daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in accordance with Brazilian national...” NCT07584122 ↗ “The HIV-1 uninfected partner was randomized in a 1:1:1 ratio to one of three arms: once daily Tenofovir Disoproxil Fumarate (TDF), Emtricitabine/Tenofovir Disoproxil Fumarate...” NCT00557245 ↗ “Tenofovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment of HIV-1 and HBV infection, respectively, but both have in vivo and in vitro...” PMID 17058225 ↗ Nov 2006 “First-line NAs (e.g. Entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), tenofovir amibufenamide (TMF)), one tablet a day, take orally,...” NCT06323681 ↗ “Tenofovir disoproxil fumarate (TDF) has been approved worldwide for the treatment of adults with chronic hepatitis B and, in combination with other antiretroviral agents, HIV-1...” PMID 24148552 ↗ Oct 2013 “For this study, the following HIV treatment (or HAART) were provided in the form of a single tablet that contains three different drugs: efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF).” NCT01403051 ↗ “the co-formulated pre-exposure prophylaxis oral pill containing tenofovir disoproxil fumarate (TDF), the prodrug of tenofovir, and FTC concurrently with the contraceptive injection DMPA” NCT03197961 ↗ “Tenofovir Disoproxil Fumarate (TDF), an approved anti-HBV drug, is promising to prevent MTCT of HBV due to its high potency against hepatitis B and its safety record in pregnant women.” NCT02995005 ↗ “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States.” NCT04666792 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily” NCT01286740 ↗ “First-Phase Viral Decay Rates in Treatment-Naive Subjects Initiating Treatment With Raltegravir (RAL) and Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF): A Pilot Study” NCT00660972 ↗ “Tenofovir disoproxil fumarate (TDF) is a prodrug of TFV (tenofovir), an adenosine nucleoside monophosphonate (nucleotide) derivative with potent antiretroviral (ARV) activity.” NCT02006264 ↗ “NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.” NCT01440569 ↗ “The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV).” NCT01509508 ↗ “NUC treatment, including tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), or entecavir (ETV), will be administered orally per local prescribing information.” NCT05763576 ↗ “This is a pilot study investigating the efficacy of Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks” NCT04429152 ↗ “coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men who have sex with men (MSM).” PMID 26123937 ↗ Jun 2015 “Participants will take tenofovir disoproxil fumarate (TDF) 300mg co-formulated with emtricitabine (FTC 200mg) once daily oral administration for preventing HIV infection.” NCT04583267 ↗ “Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.” NCT03258710 ↗ “BACKGROUND: It is unknown if tenofovir disoproxil fumarate (TDF), which is often coformulated with the lipid-neutral emtricitabine (FTC), has a lipid-lowering effect.” PMID 25870325 ↗ Apr 2015 “An Open-Label Study to Assess the Anti-HIV-1 Activity of Tenofovir Disoproxil Fumarate (TDF) in Antiretroviral-Naive Patients Who Are Chronically Infected With HIV-1” NCT00016588 ↗ “Following 3 years of randomized intervention with either tenofovir disoproxil fumarate (TDF) or placebo, participants were rolled over to open-label TDF for 3 years.” PMID 39415599 ↗ Oct 2024 “This Phase 2 study involving tenofovir disoproxil fumarate (TDF) will assess the extended safety of TDF 300 mg per day among young women who are not HIV-infected.” NCT00122486 ↗ “A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya” NCT03052010 ↗ “Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day” NCT05898841 ↗ “BACKGROUND: The safety and efficacy of tenofovir disoproxil fumarate (TDF) in HIV-1-infected children have not been evaluated in a randomized controlled trial.” PMID 25760565 ↗ Apr 2015 “Medication: Tenofovir Disoproxil Fumarate (TDF); Administration Route: Oral Dosage: 300 mg/day or 300 mg every 2 days (if creatinine clearance is 30-50 ml/min)” NCT07054359 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal” NCT01309243 ↗ “Oral nucleos(t)ide analogues (NAs) (Entecavir(ETV), Tenofovir disoproxil fumarate tablets(TDF) or Tenofovir Alafenamide Fumarate(TAF)) is used for 12-24 weeks” NCT05182463 ↗ “Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis” NCT02224456 ↗ “tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r) at nine sites in Thailand.” PMID 23075703 ↗ Jul 2012 “between danoprevir (DNV) when coadministered with low-dose ritonavir (r) and tenofovir disoproxil fumarate (TDF) or atazanavir (ATZ) in healthy volunteers” NCT01592305 ↗ “Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).” NCT02530060 ↗ “Peg-IFN-α-2β combined with first-line NAs (tenofovir disoproxil fumarate [TDF], tenofovir alafenamide fumarate [TAF], tenofovir amibufen fumarate [TMF])” NCT07553767 ↗ “Daily oral emtricitabine (FTC, F)/tenofovir disoproxil fumarate (TDF) combination is approved for HIV pre-exposure prophylaxis (PrEP) in men and women.” PMID 34041459 ↗ May 2021 “to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)” NCT03012607 ↗ “Several studies have reported improvement in lipids after antiretroviral therapy switches to tenofovir disoproxil fumarate (TDF)-containing regimens.” PMID 20495438 ↗ Jul 2010 “Maternal tenofovir disoproxil fumarate (TDF) therapy during late pregnancy can reduce mother-to-infant transmission of hepatitis B virus (HBV).” PMID 35789261 ↗ Feb 2023 “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.” NCT00507689 ↗ “93 patients would receive treatment of oral medication of tenofovir disoproxil fumarate (TDF) 300mg once per day from baseline to 48 weeks.” NCT03957629 ↗ “Tenofovir disoproxil fumarate (TDF)-based antiretroviral therapy regimens remain one of the first-line treatments in many countries.” PMID 41266678 ↗ Nov 2025 “Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily” NCT03903796 ↗ “Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert” NCT04454567 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT00892437 ↗ “Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily” NCT01108510 ↗ “Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)” NCT02065986 ↗ “Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF.” NCT02195518 ↗ “PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study.” NCT02043015 ↗ “Tenofovir disoproxil fumarate (TDF), one 300 mg tablet once a day from 28 weeks' gestation through two months postpartum” NCT03343431 ↗ “Truvada (Emtricitabine or FTC and tenofovir disoproxil fumarate or TDF) has been approved for HIV prevention since 2012.” NCT04050371 ↗ “Doravirine (DOR) in combination with Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks” NCT04433780 ↗ “Tenofovir disoproxil fumarate (TDF, Viread®) had been used as a standard treatment option of chronic hepatitis B (CHB).” PMID 35315603 ↗ Mar 2022 “Tenofovir disoproxil fumarate (TDF), a prodrug of tenofovir (TFV), may be ideal for topical HIV preexposure prophylaxis” PMID 26605514 ↗ Mar 2016 “Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase” PMID 20955704 ↗ Oct 2010 “two tablets of the fixed-dose combination of emtricitabine (FTC) 200 mg + tenofovir disoproxil fumarate (TDF) 300 mg” NCT05813964 ↗ “tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) and either efavirenz (EFV) or lopinavir/ritonavir (LPV/r)” NCT00100581 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.” NCT00896051 ↗ “tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food” NCT01533259 ↗ “PrEP involves taking one pill daily of co-formulated tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC).” NCT02870790 ↗ “Participants receive daily oral PrEP, composed of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF)” PMID 27324719 ↗ Jun 2016 “Daily DOT fixed dose combination of 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF)” NCT04937881 ↗ “100mg of doravirine (DOR), 300mg of lamivudine (3TC), and 300mg of tenofovir disoproxil fumarate (TDF)” NCT04665375 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) (300mg/200mg) on tablet once daily with food.” NCT03327155 ↗ “The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).” NCT02449733 ↗ “Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗ “TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg)” NCT02150993 ↗ “300mg tenofovir disoproxil fumarate (TDF) one tablet orally once daily for 4 wks (Day 14 to Day 42)” NCT05652478 ↗ “Plus Tenofovir Disoproxil Fumarate (TDF) and Lamivudine in a Fixed-Dose Combination Tablet (Combo)” NCT03595709 ↗ “using Tenofovir Disoproxil Fumarate plus Emtricitabine (FTC/TDF) in men and women at risk for HIV” NCT00971230 ↗ “Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.” NCT04196998 ↗ “Patients would receive treatment of oral tenofovir disoproxil fumarate (TDF) 300 mg once per day.” NCT04195074 ↗ “Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) or lamivudine (3TC) (FTC/TDF or TDF/3TC)” NCT06158126 ↗ “Sustiva (EFV 600 mg), Viread (TDF 300 mg) and Emtriva (FTC 200 mg) taken as Atripla® once-daily” NCT00752856 ↗ “tenofovir disoproxil fumarate (TDF) in an open-label, longterm extension of two phase 3 studies” PMID 23939953 ↗ Feb 2014 “Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily” NCT00737568 ↗ “Oral tablet containing 200 mg emtricitabine (FTC)/300 mg tenofovir disoproxil fumarate (TDF)” NCT04140266 ↗ “either entecavir [ETV], tenofovir disoproxil fumarate [TDF], or tenofovir alafenamide [TAF]” NCT03982186 ↗ “switch these antiretrovirals to tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)” NCT00389194 ↗ “DTG plus Tenofovir disoproxil fumarate (TDF)/XTC: Emtricitabine or lamivudine (FTC or 3TC).” PMID 40874763 ↗ Feb 2026 “Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens” NCT02862548 ↗ “Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy” NCT01671787 ↗ “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for PrEP is only licensed for adults” PMID 28873128 ↗ Nov 2017 “Tenofovir Disoproxil Fumarate(TDF) 300mg daily switch to Besifovir Dipivoxil Maleate” NCT04202536 ↗ “Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day” NCT03954327 ↗ “On Day 15, patients will add tenofovir disoproxil fumarate (TDF) to their regimens” NCT00027339 ↗ “co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)” NCT01435018 ↗ “Tenofovir disoproxil fumarate (TDF) is associated with a protective lipid profile” NCT05477407 ↗ “coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP” NCT01033942 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily” NCT01320943 ↗ “oral tenofovir disoproxil fumarate (TDF) in combination with emtricitabine (FTC)” PMID 34878438 ↗ Jan 2022 “open-label tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC)” PMID 31355775 ↗ 2019 “tenofovir disoproxil fumarate tablets (TDF), in the patients with hepatitis B” NCT04846491 ↗ “200 mg of emtricitabine [FTC], 300 mg of tenofovir disoproxil fumarate [TDF]” NCT04778514 ↗ “regimens containing tenofovir-disoproxil fumarate (TDF) for HIV prevention.” PMID 21897852 ↗ Aug 2011 “Tenofovir disoproxil fumarate (TDF) is a prodrug of a nucleotide analogue.” PMID 34222435 ↗ Jun 2021 “tenofovir disoproxil fumarate (F/TDF) as PrEP among transgender women and” PMID 38312459 ↗ Jan 2024 “TDF = tenofovir disoproxil fumarate; FTC = emtrcitabine; MVC = maraviroc” NCT02431273 ↗ “Tenofovir disoproxil fumarate + lamivudine/emtricitabine (TDF+3TC /FTC)” NCT07006246 ↗ “Tenofovir disoproxil fumarate (TDF) may be used if TAF is unavailable.” NCT07258251 ↗ “Doravirine (DOR)/Lamivudine (3TC)/Tenofovir Disproxyl Fumarate (TDF)” NCT06034938 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg tablets orally once daily” NCT02579382 ↗ “standard-of-care tenofovir disoproxil fumarate (TDF)/FTC/EFV regimen” NCT04424264 ↗ “Study of Tenofovir Disoproxil Fumarate (TDF) for Prevention of HIV” NCT00122512 ↗ “daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)” PMID 28750059 ↗ Jul 2017 “Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) tablet” NCT04692077 ↗ “Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg)” NCT02273765 ↗ “tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC)” NCT02593409 ↗ “tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg)” NCT00112047 ↗ “Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)” NCT04824131 ↗ “Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)” NCT02831764 ↗ “Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)” NCT00365612 ↗ “maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®” NCT00708162 ↗ “Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)” NCT03255915 ↗ “tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)” PMID 30212404 ↗ Sep 2018 “emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)” NCT00724711 ↗ “Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).” NCT02269917 ↗ “Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily.” NCT03476083 ↗ “tenofovir disoproxil fumarate (TDF) (TDF-based group)” PMID 31339677 ↗ Jul 2019 “tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)” NCT04760691 ↗ “Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)” NCT03386578 ↗ “DTG/tenofovir disoproxil fumarate (TDF; Viread®)/3TC” NCT06630299 ↗ “stavudine (d4T), tenofovir disoproxil fumarate (TDF)” NCT00039741 ↗ “including tenofovir disoproxil fumarate (TDF) 245mg” NCT06338826 ↗ “tenofovir disoproxil fumarate (TDF) (300 mg daily)” PMID 41644158 ↗ Feb 2026 “tenofovir disoproxil fumarate (tenofovir DF; TDF)” NCT00352053 ↗ “Tenofovir disoproxil fumarate (tenofovir DF; TDF)” NCT00298363 ↗ “Daily Tenofovir Disoproxil Fumarate (TDF; 300mg)” NCT04114890 ↗ “tenofovir disoproxil fumarate \[TDF, 300 mg\]” NCT00324649 ↗ “tenofovir disoproxil fumarate (TDF) 300 mg QD” NCT00262522 ↗ “Tenofovir disoproxil fumarate (TDF; Viread®)” NCT03491553 ↗ “Tenofovir disoproxil fumarate (TDF) tablets” NCT01300234 ↗ “Tenofovir disoproxil fumarate (TDF) 300mg” NCT01583439 ↗ “tenofovir disoproxil fumarate (TDF) 300mg” NCT01602822 ↗ “tenofovir disoproxil fumarate (TDF) 300mg” NCT01522625 ↗ “Tablet containing 200 mg FTC/300 mg TDF” NCT03593655 ↗ “tenofovir disoproxil fumarate \[TDF\]” NCT04012931 ↗ “tenofovir disoproxil fumarate (TDF)” NCT02016924 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT01040091 ↗ “tenofovir disoproxil fumarate (TDF)” NCT00102206 ↗ “tenofovir disoproxil fumarate (TDF)” NCT00336778 ↗ “tenofovir disoproxil fumarate (TDF)” NCT06337032 ↗ “TDF (Tenofovir disoproxil fumarate)” NCT00828789 ↗ “tenofovir disoproxil fumarate (TDF)” NCT00046033 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT00734162 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT02231281 ↗ “tenofovir disoproxil fumarate (TDF)” NCT03631732 ↗ “tenofovir disoproxil fumarate (TDF)” NCT02345252 ↗ “tenofovir disoproxil fumarate (TDF)” NCT01918631 ↗ “Tenofovir Disoproxil Fumarate (TDF)” NCT05423106 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT04129554 ↗ “Tenofovir DF + Efavirenz (TDF+EFV)” NCT00643968 ↗ “Tenofovir Disoproxil Fumarate（TDF）” NCT07295873 ↗ “Tenofovir disoproxil fumarate(TDF)” NCT03356834 ↗ “tenofovir disoproxil fumarate (TDF” NCT00024986 ↗ “efavirenz (EFV)/FTC/TDF” PMID 30101539 ↗ Aug 2018 “Drug: Viread® (TDF)” NCT03186482 ↗ |
| Known as | tenofovir | “This study was designed to compare the efficacy between peg-IFN alpha combined with tenofovir (TDF) and TDF monotherapy for the clearance of HBsAg in NA-experienced patients...” PMID 34697111 ↗ Oct 20214“For this study, the following HIV treatment (or HAART) were provided in the form of a single tablet that contains three different drugs: efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF).” NCT01403051 ↗ “In all groups, tenofovir disoproxil fumarate (henceforth tenofovir) was dosed at 245 mg once daily” PMID 38740027 ↗ May 2024 “emtricitabine plus tenofovir disoproxil fumarate (tenofovir) regimen” PMID 24908551 ↗ Jun 2014 “start taking tenofovir (co-formulated with emtricitabine as Truvada)” NCT00998582 ↗ |
| Known as | tenofovir DF | “The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated...” NCT00007436 ↗37“NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF,...” NCT01252940 ↗ “Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily” NCT01286740 ↗ “A single tablet regimen (STR) of efavirenz, emtricitabine and tenofovir disoproxil fumarate (tenofovir DF) is the first complete HAART that is offered as one tablet once a day.” NCT00615745 ↗ “Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily” NCT00525733 ↗ “Tenofovir DF (oral powder or tablet): 300-mg tablets for participants \> 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants ≤ 37 kg.” NCT00528957 ↗ “This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug.” NCT00002453 ↗ “Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily” NCT01254656 ↗ “Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily” NCT00737568 ↗ “UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.” NCT00824421 ↗ “Emtricitabine/tenofovir DF\* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily” NCT01147107 ↗ “Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily” NCT00507507 ↗ “tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation” NCT00362687 ↗ “tenofovir disoproxil fumarate (tenofovir DF [TDF]; 300 mg)” NCT00112047 ↗ “Tenofovir disoproxil fumarate (tenofovir DF; TDF)” NCT00298363 ↗ “Doravirine + tenofovir DF + lamivudine” NCT06602622 ↗ “Tenofovir DF + Efavirenz (TDF+EFV)” NCT00643968 ↗ “Viread (tenofovir DF, 300mg)” NCT00679926 ↗ “Viread (tenofovir DF)” NCT00106379 ↗ |
| Known as | Tenofovir disoproxil fumarate (TDF) | “Tenofovir disoproxil fumarate (TDF)” NCT03357822 ↗3“Tenofovir disoproxil fumarate (TDF)” NCT03576066 ↗ “Tenofovir disoproxil fumarate (TDF)” NCT04820686 ↗ |
| Known as | Tenofovir Disoproxil Fumarate (TDF) - brand name: Viread | “Tenofovir Disoproxil Fumarate (TDF) - brand name: Viread” NCT03780543 ↗ |
| Known as | Tenofovir Disoproxil Fumarate Tablets | “Tenofovir Disoproxil Fumarate Tablets, Nucleotide reverse transcriptase inhibitors;” NCT06566248 ↗ |
| Known as | tenofovir disoproxil fumarato | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01458977 ↗ |
| Known as | Tenofovir disoproxil;TDF | “Tenofovir disoproxil;TDF” NCT02560649 ↗ |
| Known as | Tenofovir-Disoproxil | “Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate),...” NCT04644029 ↗50“Patients randomised to the immediate arm (ARM A) will receive a 5 day PEPSE 'Home pack' containing Truvada® (tenofovir disoproxil -as fumarate- 245 mg, emtricitabine 200 mg),...” NCT04965662 ↗ “One was excluded, 200 were assigned to receive a single oral dose of 300 mg tenofovir disoproxil fumarate with 200 mg emtricitabine under direct observation, and 199 to receive...” PMID 17997151 ↗ Nov 2007 “The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV).” NCT01509508 ↗ “PrEP was prescribed as a fixed-dose combination of tenofovir disoproxil and emtricitabine (245 mg and 200 mg, respectively, per pill).” PMID 35772417 ↗ Jun 2022 “Each tablet of Truvada contains 245mg of tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)” NCT04066881 ↗ “HUG116 tablet(Tenofovir Disoproxil) with Viread® tablet(Tenofovir Disoproxil Fumarate)” NCT02902523 ↗ “Fixed dose combination of doravirine, lamivudine and tenofovir disoproxil” NCT05630638 ↗ |
| Known as | Tenolid Tab | “Switching to Tenolid Tab (Tenofovir Disoproxil) From Viread Tab (Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients” NCT05286346 ↗ |
| Known as | Viread | “Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted...” NCT03126370 ↗19“Qingzhong, a brand name of TDF, commercialized by Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd., and Viread, another brand name of TDF, commercialized by GlaxoSmithKline,...” PMID 34222435 ↗ Jun 2021 “A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet and Viread® tablet in Chronic hepatitis...” NCT02805738 ↗ “Tenofovir Disoproxil Fumarate TDF/Viread, Tenovovir Alafenamide TAF/Vemlidy, Dolutegravir DTG/Tivicay, or both TAF and DTG taken together for 4 weeks.” NCT05652478 ↗ “those in the TDF group receive TDF tablets(Viread, Aspen Port Elizabeth, China) 300 mg/d orally starting from 2-4 weeks before surgery.” NCT04032860 ↗ “Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection.” NCT00078182 ↗ “HUG116 tablet(Tenofovir Disoproxil) with Viread® tablet(Tenofovir Disoproxil Fumarate)” NCT02902523 ↗ “DTG/tenofovir disoproxil fumarate (TDF; Viread®)/3TC” NCT06630299 ↗ “Viread® tablet(Tenofovir Disoproxil Fumarate)” NCT02589457 ↗ “Tenofovir disoproxil fumarate (TDF; Viread®)” NCT03491553 ↗ “Viread (tenofovir DF)” NCT00106379 ↗ |
| Known as | Viread 245 mg | “Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg)” NCT02273765 ↗ |
| Action | Inhibit | “a potent nucleotide analogue HIV-1 reverse transcriptase (RT) inhibitor” NCT00024986 ↗ |
| Modality | Small molecule | “a potent nucleotide analogue HIV-1 reverse transcriptase (RT) inhibitor” NCT00024986 ↗ |
| Route | Oral | “administered orally” NCT00002396 ↗ |